Novartis AG ADR (NVS)

92.53
+0.14(+0.15%)
  • Volume:
    888,983
  • Bid/Ask:
    92.52/92.54
  • Day's Range:
    92.44 - 93.17

NVS Overview

Prev. Close
92.39
Day's Range
92.44-93.17
Revenue
49.88B
Open
92.43
52 wk Range
77.04-98.52
EPS
3.48
Volume
888,983
Market Cap
208.02B
Dividend (Yield)
3.20
(3.44%)
Average Vol. (3m)
1,886,122
P/E Ratio
26.57
Beta
0.57
1-Year Change
2.13%
Shares Outstanding
2,245,088,809
Next Earnings Date
Jul 21, 2021
What is your sentiment on Novartis AG ADR?
or
Vote to see community's results!

Novartis AG ADR News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellBuyStrong Buy

Novartis AG ADR Company Profile

Novartis AG ADR Company Profile

Employees
110000

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Read More
  • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
    0
    • buy
      0
      • A
        0
        • just to know. I'm lost.this is the company that bought the medicines company?
          0
          • before investing in @novartis, read #teampia (twitter).
            0
            • sell 89 expecting 80 timeframe 5 days
              1
              • Long ENDOCYTE... I work in the field
                0
                • $NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
                  0
                  • Buy this stock tomorrow as will be halted all day on Wednesday!
                    0
                    • I am willing to bet that FDA advisory committee WILL recommend their CTL019 drug!Post
                      0
                      • to the moon
                        0
                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.